Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
MORGANTOWN, W.Va., Nov. 10, 2016 -- Protea Biosciences Group, Inc., (OTCQB:PRGB) announced today that the Company has appointed David Halverson as its President.
“We are pleased to announce the selection of David Halverson as President of Protea Biosciences,” stated Steve Turner, Protea’s Chairman & CEO. He added, “David has led the successful development of our proprietary molecular information services business. He is building a strong and growing customer base, which now includes major pharmaceutical and biotechnology companies; he is ideally suited to manage our business operations, as we position Protea to meet and lead the global demand for better molecular information, for improved pharmaceutical development.”
David Halverson commented, “I am honored to be appointed to the position of President, as we continue to grow the company and add amazing new capabilities to our expanding portfolio of proprietary Metabolic, Proteomic, Biopharmaceutical, and Mass Spec Imaging workflows. I have the highest confidence in our Company achieving the leadership position in the new molecular information services industry.”
Prior to his appointment as President, Halverson served as Protea’s Vice President and Chief Business Officer. Before joining Protea, Halverson was employed by Huntingdon Life Sciences in various capacities, including Head of European and US Sales. He has over 20 years of management experience in the pharmaceutical services industry, including serving as a Director of Sales for PPD Discovery and the Quintiles Preclinical Groups.
About Protea Biosciences
Protea Biosciences Group, Inc. (OTCQB:PRGB) is a leading molecular information company providing proprietary bio-analytical technology to the pharmaceutical and life science industries. "Molecular information" refers to the generation and bioinformatic processing of very large data sets, obtained by applying the Company's proprietary technology to identify and characterize the proteins, metabolites, lipids and other biomolecules which are the byproducts of all living cells and life forms.
Protea is a registered trademark of Protea Biosciences Group, Inc.
For more Information: Protea Biosciences Group, Inc., 1311 Pineview Dr., Morgantown, WV 26505 USA Phone: 304.292.2226 Fax: 304.606.3049 https://proteabio.com/investors [email protected]
